Bioactive versus Bare Platinum Coils in the Treatment of Intracranial Aneurysms: The MAPS (Matrix and Platinum Science) Trial
Authors:
Open Access
- 30 January 2014
- journal article
- research article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 35 (5) , 935-942
Abstract
BACKGROUND AND PURPOSE: The ability of polymer-modified coils to promote stable aneurysm occlusion after endovascular treatment is not well-documented. Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited. This trial compares the effectiveness of Matrix2 polyglycolic/polylactic acid biopolymer–modified coils with bare metal coils and correlates the angiographic findings with clinical failure (ie, target aneurysm recurrence), a composite end point that includes any incident of posttreatment aneurysm rupture, retreatment, or unexplained death. MATERIALS AND METHODS: This was a multicenter randomized noninferiority trial with blinded end point adjudication. We enrolled 626 patients, divided between Matrix2 and bare metal coil groups. The primary outcome was target aneurysm recurrence at 12 ± 3 months. RESULTS: At 455 days, at least 1 target aneurysm recurrence event had occurred in 14.6% of patients treated with bare metal coils and 13.3% of Matrix2 (P = .76, log-rank test) patients; 92.8% of target aneurysm recurrence events were re-interventions for aneurysms that had not bled after treatment, and 5.8% of target aneurysm recurrence events resulted from hemorrhage or rehemorrhage, with or without retreatment. Symptomatic re-intervention occurred in only 4 (0.6%) patients. At 455 days, 95.8% of patients with unruptured aneurysms and 90.4% of those with ruptured aneurysms were independent (mRS ≤ 2). Target aneurysm recurrence was associated with incomplete initial angiographic aneurysm obliteration, presentation with rupture, and a larger aneurysmal dome and neck size. CONCLUSIONS: Tested Matrix2 coils were not inferior to bare metal coils. Endovascular coiling of intracranial aneurysms was safe, and the rate of technical success was high. Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements.Keywords
This publication has 21 references indexed in Scilit:
- The Barrow Ruptured Aneurysm TrialJournal of Neurosurgery, 2012
- Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-upThe Lancet Neurology, 2009
- Single-Institution Experience with Matrix Coils in the Treatment of Intracranial Aneurysms: Comparison with Same-Center Outcomes with the Use of Platinum CoilsAmerican Journal of Neuroradiology, 2007
- Initial clinical experience with Matrix detachable coils for the treatment of intracranial aneurysmsJournal of Neurosurgery, 2006
- Early experience with Matrix detachable coilsJournal of Neurosurgery, 2006
- Endosaccular Treatment of Intracranial Aneurysms Using Matrix CoilsStroke, 2006
- Durability of Aneurysm Embolization with Matrix Detachable CoilsNeurosurgery, 2006
- Matrix Detachable Coils for the Endovascular Treatment of Intracranial AneurysmsStroke, 2005
- International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusionThe Lancet, 2005
- Long-Term Angiographic Recurrences After Selective Endovascular Treatment of Aneurysms With Detachable CoilsStroke, 2003